IDH2 and central nervous system cancer: Glutamine metabolism importance is underscored by the robust efficacy afforded by (glutaminase) GLS inhibitors/glutamine antagonist in preclinical cancer studies6–9 and a recent phase I clinical trial for IDH mut glioma testing GLS inhibitor (NCT03528642).